Skip to main content
SpringerLink
Log in

Treatment of Pemphigus Vulgaris

Current and Emerging Options

  • Original Research Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background: Pemphigus vulgaris is a rare, chronic, autoimmune mucocutaneous blistering disease. The disease can progress to involve the skin and multiple mucosae. Pemphigus vulgaris can be associated with a high morbidity and significant mortality rate. Treatment of the condition can be challenging. Conventional therapy primarily consists of systemic corticosteroids and immunosuppressant agents. In some patients with pemphigus vulgaris, these agents fail to provide an effective clinical response or have significant adverse effects.

Methods: We evaluated data on 792 patients with pemphigus vulgaris retrieved from PubMed, covering the period 1973–2004. Only patients reported in the English literature were included in this review.

Recently, several new therapeutic agents and treatment modalities have been described for the treatment of patients with pemphigus vulgaris. Some therapeutic agents that were used in the past and abandoned have recently regained favor. This review focuses on the therapeutic uses of dapsone, methotrexate, mycophenolate mofetil, chlorambucil, dexamethasone-cyclophosphamide pulse therapy, immunoablative therapy with cyclophosphamide, plasmapheresis, and extracorporeal photochemotherapy. Newer agents, such as intravenous immunoglobulin (IVIg) therapy and rituximab (an anti-CD20 chimeric monoclonal antibody), are also discussed.

Results and conclusions: Among the oral agents, dapsone may be considered a first-line agent. This is primarily because the risk of potentially fatal adverse effects with this drug is lower than that associated with other available chemotherapeutic agents. In patients who are refractory to oral agents, alternative treatments have been used to prevent further disease progression. Recently, the use of IVIg therapy, with a defined protocol, has been reported to be beneficial. This therapy is promising since it may allow for discontinuation of all other therapies and is safe. The adverse effects from IVIg therapy are minimal. Furthermore, compared with other therapies, it provides a better quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Ahmed AR. Lymphocyte studies in pemphigus. Arch Dermatol Res. 1981; 271: 111–5

    Article  PubMed  CAS  Google Scholar 

  2. Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980; 116: 1035–7

    Article  PubMed  CAS  Google Scholar 

  3. Kanwar AJ, Kaur S. Pemphigus in children. Int J Dermatol. 1991; 30: 343–6

    Article  PubMed  CAS  Google Scholar 

  4. Wananukul S, Pongprasit P. Childhood pemphigus. Int J Dermatol. 1999; 38: 29–35

    Article  PubMed  CAS  Google Scholar 

  5. Park MS, Terasaki PI, Ahmed AR, et al. HLA-DRW4 in 91 % of Jewish pemphigus vulgaris patients. Lancet. 1979; II: 441–2

    Article  Google Scholar 

  6. Alsaleh QA, Nanda A, Al-Baghli NM, et al. Pemphigus in Kuwait. Int J Dermatol. 1999; 38: 351–6

    Article  PubMed  CAS  Google Scholar 

  7. Brautbar C, Moscovitz M, Livshits T, et al. HLA-DRw4 in pemphigus vulgaris patients in Israel. Tissue Antigens. 1980; 16: 238–43

    Article  PubMed  CAS  Google Scholar 

  8. Lever WF, Hashimoto K. The etiology and treatment of pemphigus and pemphigoid. J Invest Dermatol. 1969; 53: 373–89

    PubMed  CAS  Google Scholar 

  9. Jablonska S. Immunopathology of buttons diseases. Ann Clin Res. 1970; 2: 7–12

    PubMed  CAS  Google Scholar 

  10. Sami N, Bhol KC, Ahmed AR. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses. Clin Exp Immunol. 2001; 125: 492–8

    Article  PubMed  CAS  Google Scholar 

  11. Lenz P, Amagai M, Vole-Platzer B, et al. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Arch Dermatol. 1999; 135: 143–8

    Article  PubMed  CAS  Google Scholar 

  12. Lever WF, White H. Treatment of pemphigus with corticosteroids: results obtained in 46 patients over a period of 11 years. Arch Dermatol. 1963; 87: 12–26

    Article  PubMed  CAS  Google Scholar 

  13. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol. 1984; 120: 941–51

    Article  PubMed  CAS  Google Scholar 

  14. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989; 62: 375-91

    PubMed  CAS  Google Scholar 

  15. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996; 132: 203–12

    Article  PubMed  CAS  Google Scholar 

  16. Bystryn JC. Therapy of pemphigus. Semin Dermatol. 1988; 7: 186–94

    PubMed  CAS  Google Scholar 

  17. McDonald CJ. Cytotoxic agents for use in dermatology. I. J Am Acad Dermatol. 1985; 12: 753–75

    Article  PubMed  CAS  Google Scholar 

  18. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984; 11: 1115–26

    Article  PubMed  CAS  Google Scholar 

  19. Feltner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mt Sinai J Med. 2001; 68: 268–78

    Google Scholar 

  20. Samitz MH, Rosenberg PE. Subcorneal pustular dermatosis [letter]. Arch Dermatol. 1969; 100: 372

    Article  PubMed  CAS  Google Scholar 

  21. Mandel EH, Gonzales V. Subcomeal pustular dermatosis (Sneddon-Wilkinson). Arch Dermatol; 1969; 99: 246–7

    Article  PubMed  CAS  Google Scholar 

  22. Morgan JK, Marsden CW, Coburn JG, et al. Dapsone in dermatitis herpetiformis. Lancet. 1955; 268: 1197–200

    Article  PubMed  CAS  Google Scholar 

  23. Rogers RS, Sheridan PJ, Nightingale SH. Desquamative gingivitis: clinical, histopathologic, immunopathologic, and therapeutic observations. J Am Acad Dermatol; 1982; 7: 729–35

    Article  PubMed  Google Scholar 

  24. Buhac J, Bhol K, Padilla T, et al. Coexistence of pemphigus vulgaris and ocular cicatricial pemphigoid. J Am Acad Dermatol. 1996; 34: 884–6

    Article  PubMed  CAS  Google Scholar 

  25. Jablonska S, Chorzelski T. When and how to use sulfones in buttons diseases. Int J Dermatol. 1981; 20: 103–5

    Article  PubMed  CAS  Google Scholar 

  26. Barranco VP. Inhibition of lysosomal enzymes by dapsone. Arch Dermatol. 1974; 110: 563–6

    Article  PubMed  CAS  Google Scholar 

  27. Mier PD, van den Hurk JJ. Inhibition of lysosomal enzymes by dapsone. Br J Dermatol. 1975; 93: 471–2

    Article  PubMed  CAS  Google Scholar 

  28. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978; 156: 120–3

    Article  PubMed  CAS  Google Scholar 

  29. van Zyl JM, Basson K, Kriegler A, et al. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system: a possible correlation with their anti-inflammatory properties. Biochem Pharmacol. 1991; 42: 599–608

    Article  PubMed  Google Scholar 

  30. Thuong-Nguyen V, Kadunce DP, Hendrix JD, et al. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 1993; 100: 349–55

    Article  PubMed  CAS  Google Scholar 

  31. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993; 129: 507–13

    Article  PubMed  CAS  Google Scholar 

  32. Fraki JE, Hopsu-Havu VK. Inhibition of human skin proteinases by chloroquine, dapsone and sulfapyridine. Arch Dermatol Res. 1977; 259: 113–5

    Article  PubMed  CAS  Google Scholar 

  33. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest. 1978; 62: 214–20

    Article  PubMed  CAS  Google Scholar 

  34. Jeffes EW, Kaplan RP, Ahmed AR. Acantholysis produced in vitro with pemphigus serum: hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis. J Clin Immunol. 1984; 4: 359–63

    Article  PubMed  CAS  Google Scholar 

  35. Chiang H, Sirois DA, Bielory L. Chronic oral mucosal ulceration in a 54-year-old female. Ann Allergy Asthma Immunol. 2000; 84: 391–5

    Article  PubMed  CAS  Google Scholar 

  36. DeMento FJ, Grover RW. Acantholytic herpetiform dermatitis. Arch Dermatol. 1973; 107: 883–7

    Article  PubMed  CAS  Google Scholar 

  37. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976; 94: 681–6

    Article  PubMed  CAS  Google Scholar 

  38. Pearson RW, O’Donoghue M, Kaplan SJ. Pemphigus vegetans: its relationship to eosinophilic spongiosis and favorable response to dapsone. Arch Dermatol. 1980; 116: 65–8

    Article  PubMed  CAS  Google Scholar 

  39. Ahmed AR, Salm M. Juvenile pemphigus. J Am Acad Dermatol. 1983; 8799–80

  40. Rodan KP, Hu CH, Nickoloff BJ. Malodorous intertriginous pustules and plaques: pppemphigus vegetans, Hallopeau type. Arch Dermatol. 1987; 123 (3): 393, 396–7

    Google Scholar 

  41. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987; 17: 437–42

    Article  PubMed  CAS  Google Scholar 

  42. Barnard GF, Scharf MJ, Dagher RK. Sulfone syndrome in a patient receiving steroids for pemphigus. Am J Gastroenterol. 1994; 89: 2057–9

    PubMed  CAS  Google Scholar 

  43. Bjarnason B, Skoglund C, Flosadottir E. Childhood pemphigus vulgaris treated with dapsone: a case report. Pediatr Dermatol. 1998; 15: 381–3

    Article  PubMed  CAS  Google Scholar 

  44. Tan HH, Tay YK. An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clin Exp Dermatol. 2000; 25: 224–6

    Article  PubMed  CAS  Google Scholar 

  45. Jetton RL. Methotrexate and its uses in dermatology. Med Times. 1970; 98: 83–92

    PubMed  CAS  Google Scholar 

  46. Ashton H, Beveridge GW, Stevenson CJ. Therapeutics: XI. Immunosuppressive drugs. Br J Dermatol. 1970; 83: 326–30

    Article  PubMed  CAS  Google Scholar 

  47. Peck SM. How I treat pemphigus vulgaris. Postgrad Med. 1970; 48: 271–3

    PubMed  CAS  Google Scholar 

  48. Tuffanelli DL. Pemphigus. Clin Pharmacol Ther. 1974; 16: 974–9

    PubMed  CAS  Google Scholar 

  49. Rudolph RI, Leyden JJ. Dermatologic therapy with immunosuppressive agents. Postgrad Med. 1975; 58: 103–8

    PubMed  CAS  Google Scholar 

  50. Lynch PJ, Gallego RE, Saied NK. Pemphigus: a review. Ariz Med. 1976; 33: 1030–7

    PubMed  CAS  Google Scholar 

  51. Adam BA. Buttons diseases in Malaysia: epidemiology and natural history. Int J Dermatol. 1992; 31: 42–5

    Article  PubMed  CAS  Google Scholar 

  52. Peck SM, Osserman KE. Studies in buttons diseases: treatment of pemphigus vulgaris with methotrexate, two patients (one with concurrent myasthenia gravis). J Mt Sinai Hosp N Y. 1969; 36: 71–6

    PubMed  CAS  Google Scholar 

  53. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol. 1969; 100: 70–8

    Article  PubMed  CAS  Google Scholar 

  54. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol. 1970; 83: 315–23

    Article  PubMed  CAS  Google Scholar 

  55. Haim S, Shafrir A. Remarks on the treatment of pemphigus vulgaris. Dermatologica. 1970; 141: 270–6

    Article  PubMed  CAS  Google Scholar 

  56. Lever WF. Pemphigus vulgaris. Arch Dermatol. 1970; 102: 114–6

    Article  PubMed  CAS  Google Scholar 

  57. Peck SM, Osserman KE, Samuels AJ, et al. Studies in buttons diseases: treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol. 1971; 103: 141–7

    Article  PubMed  CAS  Google Scholar 

  58. Ryan JG. Pemphigus: a 20-year survey of experience with 70 cases. Arch Dermatol. 1971; 104: 14–20

    Article  PubMed  CAS  Google Scholar 

  59. Lever WF. Methotrexate and prednisone in pemphigus vulgaris: therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972; 106: 491–7

    Article  PubMed  CAS  Google Scholar 

  60. Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai. 1975; 58: 171–6

    PubMed  CAS  Google Scholar 

  61. Haim S, Friedman-Bimbaum R. Pyoderma gangrenosum in immunosuppressed patients. Dermatologica. 1976; 153: 44–8

    Article  PubMed  CAS  Google Scholar 

  62. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris: a 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988; 68: 413–21

    PubMed  CAS  Google Scholar 

  63. Lever WE Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977; 113: 1236–41

    Article  PubMed  CAS  Google Scholar 

  64. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999; 135: 1275–6

    Article  PubMed  CAS  Google Scholar 

  65. Guzzo C. Folic acid supplementation with methotrexate therapy: what benefit if any? [letter]. J Am Acad Dermatol. 1994; 31: 689

    Article  PubMed  CAS  Google Scholar 

  66. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999; 135: 54–6

    Article  PubMed  CAS  Google Scholar 

  67. Moore R, Griffin P, Darby C, et al. Mycophenolate mofetil for prevention of acute rejection [letter]. Lancet. 1995; 346: 253

    Article  PubMed  CAS  Google Scholar 

  68. Lynch WS, Roenigk HH. Mycophenolic acid for psoriasis. Arch Dermatol. 1977; 113: 1203–8

    Article  PubMed  CAS  Google Scholar 

  69. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc. 1991; 23: 19–25

    PubMed  Google Scholar 

  70. Bohm M, Beissert S, Schwarz T, et al. Buttons pemphigoid treated with mycophenolate mofetil [letter]. Lancet. 1997; 349: 541

    Article  PubMed  CAS  Google Scholar 

  71. Ratnam KV. Adjuvant therapy of bullous pemphigoid with mycophenolate mofetil: old drug, new use. Singapore Med. 12001; 42: 482–4

    Google Scholar 

  72. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999; 40: 265–8

    Article  PubMed  CAS  Google Scholar 

  73. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil [letter]. Lancet. 1997; 350: 494

    Article  PubMed  CAS  Google Scholar 

  74. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999; 40: 957–60

    Article  PubMed  CAS  Google Scholar 

  75. Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of pemphigus vulgaris and buttons pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol. 1999; 135: 724–5

    Article  PubMed  CAS  Google Scholar 

  76. Bredlich RO, Grundmann-Kollmann M, Behrens S, et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris [letter]. Br J Dermatol. 1999; 141: 934

    Article  PubMed  CAS  Google Scholar 

  77. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996; 348: 1357–9

    Article  PubMed  CAS  Google Scholar 

  78. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997; 37: 445–9

    Article  PubMed  CAS  Google Scholar 

  79. Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987; 17: 962–71

    Article  PubMed  CAS  Google Scholar 

  80. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol. 1999; 135: 853–4

    Article  PubMed  CAS  Google Scholar 

  81. Bystryn JC. Is mycophenolic acid effective for the treatment of pemphigus?. Arch Dermatol. 1999; 135: 854–5

    Article  PubMed  CAS  Google Scholar 

  82. Popovsky JL, Camisa C. New and emerging therapies for diseases of the oral cavity. Dermatol Clin. 2000; 18: 113–25

    PubMed  CAS  Google Scholar 

  83. Shah N, Green AR, Elgart GW, et al. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol. 2000; 42: 85–8

    Article  PubMed  CAS  Google Scholar 

  84. Aeschlimann A, Brackertz D, Kaiser H, et al. Chlorambucil pulse therapy in progressive chronic polyarthritis. Initial results of an open multicenter study [in German]. Z Rheumatol. 1987; 46: 241–4

    PubMed  CAS  Google Scholar 

  85. Snaith ML, Holt JM. Chlorambucil in the treatment of systemic lupus erythematosus. Am Heart J. 1974; 87: 533–5

    Article  PubMed  CAS  Google Scholar 

  86. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993; 36: 319–24

    Article  PubMed  CAS  Google Scholar 

  87. Elliott JH, Ballinger WH. Behcet’s syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc. 1984; 82: 264–81

    PubMed  CAS  Google Scholar 

  88. Edwards JC, Leandro MJ, Cambridge G. B-Lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002; 30: 824–8

    Article  PubMed  CAS  Google Scholar 

  89. Shvidel L, Klepfish A, Berrebi A. Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin’s lymphoma. Am J Hematol. 2001; 67: 213–4

    Article  PubMed  CAS  Google Scholar 

  90. Layios N, Van Den Neste E, Jost E, et al. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia. 2001; 15: 187–8

    Article  PubMed  CAS  Google Scholar 

  91. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001; 66: 142–4

    Article  PubMed  CAS  Google Scholar 

  92. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004; 140: 91–6

    Article  PubMed  CAS  Google Scholar 

  93. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases: successful result in refractory pemphigus vulgaris: report of a case [letter]. Haematologica. 2003; 88: ELT24

    PubMed  Google Scholar 

  94. Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol. 2003; 28: 366–8

    Article  PubMed  CAS  Google Scholar 

  95. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003; 148: 602–3

    Article  PubMed  CAS  Google Scholar 

  96. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002; 47: 785–8

    Article  PubMed  Google Scholar 

  97. Arm MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (Rituximab) in the treatment of pemphigus. Br J Dermatol. 2005; 153 (3): 620–5

    Article  CAS  Google Scholar 

  98. Schmidt E, Herzog S, Brocker EB. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005; 153 (2): 449–51

    Article  PubMed  CAS  Google Scholar 

  99. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (Rituximab). J Am Acad Dermatol. 2004; 51 (5): 817–9

    Article  PubMed  Google Scholar 

  100. Espana A, Femandez-Galar M, Lloret P, et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004; 50 (6): 974–6

    Article  PubMed  Google Scholar 

  101. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988; 119: 73–7

    Article  PubMed  CAS  Google Scholar 

  102. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990; 29: 371–4

    Article  PubMed  CAS  Google Scholar 

  103. Feltner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978; 114: 889–94

    Article  Google Scholar 

  104. Cummins DL, Mimouni D, Anhalt GJ, et al. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003; 49: 276–80

    Article  PubMed  Google Scholar 

  105. Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982; 62: 491–6

    PubMed  CAS  Google Scholar 

  106. Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol. 1992; 31: 875–7

    Article  PubMed  CAS  Google Scholar 

  107. Pasricha JS, Khaitan BK, Raman RS, et al. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol. 1995; 34: 875–82

    Article  PubMed  CAS  Google Scholar 

  108. Kumrah L, Ramam M, Shah P, et al. Pituitary-adrenal function following dexamethasone-cyclophosphamide pulse therapy for pemphigus. Br J Dermatol. 2001; 145: 944–8

    Article  PubMed  CAS  Google Scholar 

  109. Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002; 204: 228–31

    Article  PubMed  CAS  Google Scholar 

  110. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992; 128: 1626–30

    Article  PubMed  CAS  Google Scholar 

  111. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol. 2000; 43: 1065–9

    Article  PubMed  CAS  Google Scholar 

  112. Ruocco V, Rossi A, Argenziano G, et al. Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol. 1978; 98: 237–41

    Article  PubMed  CAS  Google Scholar 

  113. Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris [letter]. Br J Dermatol. 1978; 98: 243

    Article  PubMed  CAS  Google Scholar 

  114. Meurer M, Braun-Falco O. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol. 1979; 100: 231–2

    Article  PubMed  CAS  Google Scholar 

  115. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy: effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol. 1979; 115: 728–30

    Article  PubMed  CAS  Google Scholar 

  116. Coverton RW, Armstrong RB. Acanthosis nigricans developing in resolving lesions of pemphigus vulgaris. Arch Dermatol. 1982; 118: 115–6

    Article  PubMed  CAS  Google Scholar 

  117. Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica. 1984; 168: 219–23

    Article  PubMed  CAS  Google Scholar 

  118. Enter HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol. 1987; 123: 1205–10

    Article  Google Scholar 

  119. Fine JD, Appell ML, Green LK, et al. Pemphigus vulgaris: combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988; 124: 236–9

    Article  PubMed  CAS  Google Scholar 

  120. Blaszczyk M, Chorzelski TP, Jablonska S, et al. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol. 1989; 125: 843–4

    Article  PubMed  CAS  Google Scholar 

  121. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990; 22: 35–40

    Article  PubMed  CAS  Google Scholar 

  122. Sondergaard K, Carstens J, Jorgensen J, et al. The steroid-sparing effect of longterm plasmapheresis in pemphigus. Acta Derm Venereol. 1995; 75: 150–2

    PubMed  CAS  Google Scholar 

  123. Thakur BK, Bernardi DM, Murali MR, et al. Invasive cutaneous aspergillosis complicating immunosuppressive therapy for recalcitrant pemphigus vulgaris. J Am Acad Dermatol. 1998; 38: 488–90

    Article  PubMed  CAS  Google Scholar 

  124. Ogata K, Yasuda K, Matsushita M, et al. Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. J Dermatol. 1999; 26: 236–9

    PubMed  CAS  Google Scholar 

  125. Yano C, Ishiji T, Kamide R, et al. A case of pemphigus vulgaris successfully treated with single filtration plasmapheresis: a correlation of clinical disease activity with serum antibody levels. J Dermatol. 2000; 27: 380–5

    PubMed  CAS  Google Scholar 

  126. Shapiro M, Jimenez S, Werth VP. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol. 2000; 42: 297–9

    Article  PubMed  CAS  Google Scholar 

  127. Turner MS, Sutton D, Sander DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000; 43: 1058–64

    Article  PubMed  CAS  Google Scholar 

  128. Bystryn JC, Graf MW, Um JW. Regulation of antibody formation by serum antibody: II. Removal of specific antibody by means of exchange transfusion. J Exp Med. 1970; 132: 1279–87

    Article  PubMed  CAS  Google Scholar 

  129. Sams WM, Schur PH. Studies of the antibodies in pemphigoid and pemphigus. J Lab Clin Med. 1973; 82: 249–54

    PubMed  Google Scholar 

  130. Jones JV. Response to apheresis: problems of assessment in immune disease. Clin Nephrol. 1986; 26 Suppl. 1: S70–5

    PubMed  Google Scholar 

  131. Hida MTT, Kitatnma M, Iida T, et al. Clinical reports on plasma exchange in the Kidney Center, Tokai University School of Medicine. Tokai J Exp Clin Med. 1987; 12: 61–6

    PubMed  CAS  Google Scholar 

  132. Stanley JR. Pathophysiology and therapy of pemphigus in the 21st century. J Dermatol. 2001; 28: 645–6

    PubMed  CAS  Google Scholar 

  133. Wenz B, Barland P. Therapeutic intensive plasmapheresis. Semin Hematol. 1981; 18: 147–62

    PubMed  CAS  Google Scholar 

  134. Terman DS, Garcia-Rinaldi R, Dannemann B, et al. Specific suppression of antibody rebound after extracorporeal immunoadsorption: I. Comparison of single versus combination chemotherapeutic agents. Clin Exp Immunol. 1978; 34: 32–41

    PubMed  CAS  Google Scholar 

  135. Derksen RH, Schumman HJ, Gmelig Meyling FH, et al. Rebound and overshoot after plasma exchange in humans. J Lab Clin Med. 1984; 104: 35–43

    PubMed  CAS  Google Scholar 

  136. Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus: uncontrolled study of ten patients. Arch Dermatol. 1983; 119: 215–21

    Article  PubMed  CAS  Google Scholar 

  137. Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal?. Arch Dermatol. 1988; 124: 1716–8

    Article  PubMed  CAS  Google Scholar 

  138. Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988; 124: 1702–4

    Article  PubMed  CAS  Google Scholar 

  139. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988; 124: 1659–63

    Article  PubMed  CAS  Google Scholar 

  140. Roujeau JC. Plasmapheresis therapy of pemphigus and buttons pemphigoid. Semin Dermatol. 1988; 7: 195–200

    PubMed  CAS  Google Scholar 

  141. Korman N. Pemphigus. J Am Acad Dermatol. 1988; 18: 1219–38

    Article  PubMed  CAS  Google Scholar 

  142. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant. 1994; 14: 845–8

    Article  PubMed  CAS  Google Scholar 

  143. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter trial. Arch Dermalot. 1992; 128: 337–46

    Article  CAS  Google Scholar 

  144. Knobler RM, Graninger W, Lindmaier A, et al. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus: a pilot study. Arthritis Rheum. 1992; 35: 319–24

    Article  PubMed  CAS  Google Scholar 

  145. Heald P, Knobler R, LaRoche L. Photoinactivated lymphocyte therapy of cutaneous T-cell lymphoma. Dermatol Clin. 1994; 12: 443–9

    PubMed  CAS  Google Scholar 

  146. Edelson RL. Photopheresis: a new therapeutic concept. Yale J Biol Med. 1989; 62: 565–77

    PubMed  CAS  Google Scholar 

  147. Rook AH, Cohen JH, Lessin SR, et al. Therapeutic applications of photopheresis. Dermatol Clin. 1993; 11: 339–47

    Article  PubMed  CAS  Google Scholar 

  148. Gross M, Bob EE, Millikan LE. Extracorporeal photopheresis. Int J Dermatol. 1994; 33: 407–11

    Article  PubMed  CAS  Google Scholar 

  149. Edelson RL. Photopheresis: a clinically relevant immunobiologic response modifier. Ann N Y Acad Sci. 1991; 636: 154–64

    Article  PubMed  CAS  Google Scholar 

  150. Azana JM, de Misa RF, Harto A, et al. Severe pemphigus foliaceus treated with extracorporeal photochemotherapy. Arch Dermatol. 1997; 133: 287–9

    Article  PubMed  CAS  Google Scholar 

  151. Perotti C, Torretta L, Viarengo G, et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica. 1999; 84: 237–41

    PubMed  CAS  Google Scholar 

  152. Efferth T, Fabry U, Osieka R. Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro. Anticancer Res. 2001; 21: 2777–83

    PubMed  CAS  Google Scholar 

  153. Rook AH, Jegasothy BV, Heald P, et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med. 1990; 112: 303–5

    PubMed  CAS  Google Scholar 

  154. Rook AH, Heald PW, Nahass GT, et al. Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris: preliminary report. Yale J Biol Med. 1989; 62: 647–52

    PubMed  CAS  Google Scholar 

  155. Rook AH. Photopheresis in the treatment of autoimmune disease: experience with pemphigus vulgaris and systemic sclerosis. Ann N Y Acad Sci. 1991; 636: 209–16

    Article  PubMed  CAS  Google Scholar 

  156. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol. 1992; 26: 779–80

    Article  PubMed  CAS  Google Scholar 

  157. Gollnick HP, Owsianowski M, Taube KM, et al. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol. 1993; 28: 122–4

    Article  PubMed  CAS  Google Scholar 

  158. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune buttons diseases. Dermatology. 1999; 198: 140–4

    Article  PubMed  CAS  Google Scholar 

  159. Wolfe JT, Lessin SR, Singh AH, et al. Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. Artif Organs. 1994; 18: 888–97

    Article  PubMed  CAS  Google Scholar 

  160. Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; I: 1228–31

    Article  Google Scholar 

  161. Abe T, Kawasugi K. Use of intravenous immunoglobulin in various medical conditions: a Japanese experience. Cancer. 1991; 68: 1454–9

    Article  PubMed  CAS  Google Scholar 

  162. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol. 1999; 140: 865–74

    Article  PubMed  CAS  Google Scholar 

  163. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol. 1989; 20: 684–5

    Article  PubMed  CAS  Google Scholar 

  164. Humbert P, Derancourt C, Aubin F, et al. Effects of intravenous gamma-globulin in pemphigus [letter]. J Am Acad Dermatol. 1990; 22: 326

    Article  PubMed  CAS  Google Scholar 

  165. Messer G, Sizmann N, Feucht H, et al. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol. 1995; 133: 1014–6

    Article  PubMed  CAS  Google Scholar 

  166. Beckers RC, Brand A, Vermeer BJ, et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and buttons pemphigoid: experience in six patients. Br J Dermatol. 1995; 133: 289–93

    Article  PubMed  CAS  Google Scholar 

  167. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol. 1996; 135: 128–9

    Article  PubMed  CAS  Google Scholar 

  168. Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol. 1996; 135: 862–3

    Article  PubMed  CAS  Google Scholar 

  169. Colonna L, Cianchini G, Frezzolini A, et al. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy?. Br J Dermatol. 1998; 138: 1102–3

    Article  PubMed  CAS  Google Scholar 

  170. Jolles S, Hughes J, Rustin M. Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. J Am Acad Dermatol. 1999; 40: 499–500

    Article  PubMed  CAS  Google Scholar 

  171. Engineer L, Norton LA, Ahmed AR. Nail involvement in pemphigus vulgaris. J Am Acad Dermatol. 2000; 43: 529–35

    Article  PubMed  CAS  Google Scholar 

  172. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001; 45: 679–90

    Article  PubMed  CAS  Google Scholar 

  173. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002; 138: 1158–62

    Article  PubMed  CAS  Google Scholar 

  174. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol. 2000; 43: 1049–57

    Article  PubMed  CAS  Google Scholar 

  175. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003; 139 (8): 1051–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Oral Medicine, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, Massachusetts, MA 02115, USA

    Shih Wei Yeh, Naveed Sami &  Razzaque A. Ahmed

  2. Department of Medicine, Center for Blistering Diseases, New England Baptist Hospital, Boston, Massachusetts, USA

    Naveed Sami &  Razzaque A. Ahmed

  3. Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA

    Razzaque A. Ahmed

Authors
  1. Shih Wei Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naveed Sami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Razzaque A. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Razzaque A. Ahmed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeh, S.W., Sami, N. & Ahmed, R.A. Treatment of Pemphigus Vulgaris. Am J Clin Dermatol 6, 327–342 (2005). https://doi.org/10.2165/00128071-200506050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506050-00006

Keywords

Search

Navigation